Cytokinetics Inc
CYTK
Market Cap$3.7B
Close$
$-11.38
135.5% downside
Current Fair Value
135.5% downsideOvervalued by 135.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.70 Billion |
|---|---|
| Enterprise Value | $4.47 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.26 |
| Beta | 0.81 |
| Outstanding Shares | 118,496,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.97 |
|---|---|
| PEG | -31.49 |
| Price to Sales | - |
| Price to Book Ratio | -10.69 |
| Enterprise Value to Revenue | 232.82 |
| Enterprise Value to EBIT | -8.37 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -3.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum